CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$0.72−0.02 (-2.35%)

Close on Oct 19, 2026

Market cap: $2.68M
P/E (TTM): –
Dividend yield: –

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.02	0.07	0.07	0.09	0.14	0.09	0.10	0.09	0.04	0.10	0.12	0.16	–	–	–	–	0.23	0.22	0.17	0.12	0.07	0.02	0.01	0.00	0	0	0	0	0
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.00	0.00	0.01	0.02	0.02	0.03	0.06	0.05	0.05	0.05	0.02	0.03	0.04	0.05	0.05	0.04	0.05	0.05	0.07	0.10	0.08	0.07	0.05	0.01	0.01	0.01	–	–	–	–	–
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.05	0.05	0.06	0.08	0.04	0.05	0.04	0.02	0.07	0.09	0.11	0.10	0.09	0.11	0.12	0.16	0.12	0.08	0.05	0.02	0.01	0.00	0.00	–	–	–	–	–
Research & Development	2.02	2.06	2.26	2.18	2.30	2.72	2.40	2.28	2.69	2.07	1.97	6.99	6.23	6.58	6.27	0.95	0.78	0.12	0.11	0.06	0	–	0	–	–	–	0	0.09	0.09	0.09	0.10	0.10	0.18	0.20	0.26	0.19	0.15	0.14	0.09	–
Selling, General & Admin	4.11	3.76	3.76	3.79	3.51	3.46	3.24	3.24	3.28	3.46	3.56	3.06	3.34	3.58	3.94	4.47	4.42	3.81	2.96	1.85	1.38	1.10	1.16	1.16	1.19	1.29	1.22	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.17	1.13	1.13	1.05	0.94	0.86	0.92	0.90	0.92	0.88	0.70	0.66	–
Operating Expenses	6.24	5.94	6.15	6.09	5.92	6.29	5.75	5.64	6.07	5.64	5.63	10	9.66	10	10	5.51	5.29	4.02	3.17	2.00	1.46	1.17	1.23	1.22	1.24	1.33	1.25	1.28	1.24	1.24	1.17	1.06	1.07	1.15	1.17	1.12	1.04	0.85	0.76	0.57
Operating Income	-6.24	-5.94	-6.14	-6.08	-5.92	-6.28	-5.74	-5.63	-6.06	-5.63	-5.62	-10	-9.60	-10	-10	-5.44	-5.25	-3.98	-3.13	-1.98	-1.39	-1.08	-1.11	-1.12	-1.15	-1.21	-1.13	-1.12	-1.12	-1.16	-1.11	-1.04	-1.06	-1.14	-1.18	-1.12	-1.04	-0.85	-0.76	-0.58
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	0.00	0	2.40	3.71	3.94	4.28	2.20	1.18	1.24	1.23	1.32	1.56	1.76	1.90	1.87	1.72	1.62	1.36	1.16	0.92	0.57	0.38	0.20	0.07	0.01	0.01	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	0.03	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	0.20	0.18	0.15	0.12	0.15	0.19	0.25	0.31	0.33	0.35	0.33	0.30	0.25	0.16	0.10	-2.36	-3.41	-5.80	22	-14	-12	-11	-35	-1.77	-4.54	-2.73	-7.35	-0.24	0.60	-5.71	-13	-16	-14	-8.86	-1.48	-0.25	-0.50	-0.01	-0.01	–
Pretax Income	-6.04	-5.76	-6.00	-5.96	-5.77	-6.09	-5.49	-5.32	-5.73	-5.28	-5.29	-9.82	-9.35	-10	-10	-7.80	-8.67	-9.78	19	-16	-13	-12	-36	-2.90	-5.70	-3.94	-8.48	-1.36	-0.52	-6.87	-14	-17	-16	-10	-2.66	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–	0	–	–	–	0	–	–	0	0	0	0	0	0	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-5.77	-6.09	-5.49	-5.32	-5.73	-5.28	-5.29	-18	-17	-21	-10	37	40	48	19	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-6.04	-5.76	-6.00	-5.96	-5.77	-6.09	-5.49	-5.32	-5.73	-5.28	-5.29	-9.82	-9.35	-10	-10	-7.80	-8.67	-9.78	19	-16	-13	-12	-36	-2.90	-5.70	-3.94	-8.48	-1.36	-0.52	-6.87	-14	-17	-16	-10	-2.66	-1.38	-1.54	-0.86	-0.77	-0.58
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	19	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.93	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.07
EPS (Diluted)(per share)	-1.97	-2.04	-2.52	–	–	–	–	–	–	–	–	–	–	–	-0.93	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.07
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	–	–	–	–	–	–	–	–	–	–	11	8.25	5.35	3.68	2.61	–	–	–	–	57	435	394	10	383	5.93	5.19	3.91	2.76	1.71	0.85	0.71	0.70	0.69	0.67	0.63	0.48
Shares Outstanding (Diluted, Weighted)(shares)	3.17	2.89	2.38	2.21	1.91	1.62	1.48	–	–	–	–	–	–	–	11	8.86	5.96	294	3.25	–	–	–	–	241	619	578	10	383	5.93	5.19	3.91	2.76	1.71	0.85	0.71	0.70	0.69	0.67	0.63	0.48
EBITDA	–	–	–	–	–	-6.23	-5.69	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 66.9%
Operating margin: -208004.4%
Net margin: -201355.4%
Return on equity, FY2025: -86.5%

Financial strength

Current ratio: 12.91
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1247.4%

Valuation

P/E ratio: –
Price to sales: 892.84
Price to book: 0.31
Dividend yield: –